Combination of Inecalcitol with tyrosine kinase inhibitor - CML
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
Inecalcitol inhibits the proliferation in vitro of stem cells of patients with CML in synergy with Imatinib, Nilotinib or Dasatinib
Inecalcitol inhibits the proliferation in vitro of stem cells of patients with CML in synergy with Imatinib, Nilotinib or Dasatinib
ARTICLES
Hybrigenics gives update on chronic myeloid leukemia study
February 10, 2017, pharmaceutical daily news
Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells, Activates a Macrophage Differentiation Pathway in Leukemic Progenitors
December 7, 2015, ASH 2015
BRIEF-Hybrigenics to present new in vitro data on inecalcitol in chronic myeloid leukemia
November 19, 2015, Reuters
Hybrigenics Presents New in Vitro Results on Inecalcitol in Chronic Myeloid Leukemia at the AACR Meeting in Philadelphia, USA
April 20, 2015, Evaluate Group
Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia
January 19, 2015, LSP
